Loading...
XHKG
1345
Market cap306mUSD
Oct 07, Last price  
2.08HKD
1D
-2.12%
1Q
-9.78%
Jan 2017
-25.89%
IPO
-47.47%
Name

Shanghai Pioneer Holding Ltd

Chart & performance

D1W1MN
XHKG:1345 chart
P/E
17.98
P/S
1.60
EPS
0.10
Div yield, %
5.78%
Shrs. gr., 5y
-0.98%
Rev. gr., 5y
-0.74%
Revenues
1.28b
-16.17%
570,647,000717,831,000958,723,0001,272,247,0001,540,398,0001,460,899,0001,790,275,0002,153,935,0001,624,305,0001,315,978,0001,332,037,0001,434,820,0001,556,040,0001,566,673,0001,531,050,0001,283,425,000
Net income
114m
-24.56%
70,435,00095,675,000186,369,000238,372,000261,718,000174,302,000237,445,000278,925,00084,597,000104,627,00052,448,000142,633,000235,296,000145,718,000151,618,000114,383,000
CFO
215m
+0.21%
71,205,000-21,777,000120,758,00047,937,000-17,778,000304,690,000342,039,000233,628,000128,667,000280,642,00074,239,000242,064,00093,295,000-118,686,000214,831,000215,272,481
Dividend
Nov 19, 20260.056 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

China Pioneer Pharma Holdings Limited operates as an investment holding company, primarily focusing on the marketing, promotion, and distribution of pharmaceutical goods and medical devices within mainland China. The firm maintains an extensive portfolio of pharmaceutical products addressing diverse therapeutic areas, including ophthalmology, pain management, cardiovascular health, immunology, gynecology, and gastroenterology. Its medical device offerings encompass solutions for ophthalmology, orthopedics, dentistry, and wound care. The company supplies its products to a wide client base, including hospitals, various medical institutions, and pharmacies. Additionally, it engages in the sale of supporting tools, leases related equipment, provides dental apparatus, and distributes imported prescription products under license. Established in 1996, China Pioneer Pharma Holdings Limited is headquartered in Shanghai, PRC, and functions as a subsidiary of Pioneer Pharma (BVI) Co., Ltd.

Key people

Yi Xue
Chief Financial Officer · since 2016
Wenfei Huang
General Manager - Ophthalmology Business Unit · since 2014
Rongrong Wang
General Manager - Alcon Business Unit, National Director - Commerce Department · since 2016
Xiuyan Yang
General Manager - Polichem Business Unit · since 2015
Executive Chairman of the Board · since 2015
Guoguang Xiao
Executive Director · since 2020
Yuewen Yang
Chief Operating Officer, Executive Director · since 2022
Quan Zhang
Executive Director · since 2023
Tao Wang
Business Development Director · since 2020
Yue Yu
Government Affairs Director · since 2017
Ka Man Ng
Company Secretary · since 2020
Mingfei Hu
Non-Executive Director · since 2020
Chanshu Lai
Non-Executive Independent Director · since 2021
Changhai Zhang
Non-Executive Independent Director · since 2024
Hong Zhang
Non-Executive Independent Director · since 2019
IPO date
Nov 05, 2013
Employees
361
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT